# A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

> **NCT01166490** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 51 (actual)

## Conditions studied

- Gastric Neoplasms
- Pancreatic Neoplasms

## Interventions

- **DRUG:** ASG-5ME

## Key facts

- **NCT ID:** NCT01166490
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2013-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01166490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01166490, "A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01166490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*